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Abstract
Background: Chronic edema (CO) is a complex condition, arising from different factors, including immobility
and obesity. Edema and obesity can have a significant impact on quality of life of patients and their families.
Understanding how to manage edema in obese patients is an increasing challenge for both patients and clinicians.
As effective treatment options are limited for this population, it is more cost-effective for patients to lose weight
before starting treatment. When patients cannot maintain weight loss, one option is to have bariatric surgery.
This study was part of LIMPRINT: Lymphedema IMpact and PRevalence INTernational, a study with the aim
of identifying the prevalence and impact of CO in different countries and health care settings.
Study Purpose: To evaluate the prevalence and impact of CO among patients in a United Kingdom bariatric
surgical service.
Methods and Results: The gold standard pitting test assessed the presence of edema. General (EuroQOL-5
Dimensions [EQ-5D], RAND 36-Item Short Form Health Survey, Version 1.0 [SF-36], Generalized Anxiety
Disorder 7-Item Scale [GAD-7] and Patient Health Questionnaire–9 [PHQ-9]), and edema-specific (Lymphedema
Quality of Life [LYMQOL]) quality-of-life questionnaires were used to evaluate impact of edema.
The prevalence of edema was 52.1% (25 of 48 participants had edema), potentially linked to obesity, immo-
bility, and medications. Most participants had International Society of Lymphology (ISL) Stage I edema. There
were no statistically significant differences between the quality of life of participants with and without edema.
However, comparing SF-36 results and normative population data indicated that quality of life was much lower
than those in the normative population.
Conclusions: This study highlights the high prevalence of edema and low quality of life of this bariatric
population. ClinicalTrials.gov ID: NCT03154593.
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Introduction
Chronic edema
The definition of chronic edema (CO) is: persistentswelling, present for 3 months or more.1 It is primarily
found in the upper and lower limbs, but can be present
throughout the body.1,2
CO is complex and occurs due to different causes and
mechanisms, including immobility, inefficient lymph drain-
age, chronic venous disease, and obesity.1,2 If CO becomes
1University Hospitals of Derby and Burton NHS Foundation Trust, Royal Derby Hospital, Derby, United Kingdom.
2School of Medicine, Royal Derby Hospital Centre, University of Nottingham, Derby, United Kingdom.
3Centre for Research and Implementation of Clinical Practice, London, United Kingdom.
4Copenhagen Wound Healing Centre, Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.




ª Amy Newman et al. 2021; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative
Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
LYMPHATIC RESEARCH AND BIOLOGY
Volume 19, Number 5, 2021
Mary Ann Liebert, Inc.
DOI: 10.1089/lrb.2021.0055
431
worse, it can result in cellulitis and skin conditions (like
chronic lipodermatosclerosis and lymphangiectasia).3,4
The main treatment of CO is through decongestive lym-
phedema therapy (DLT), a combination of skin care to reduce
infection risk, and compression bandaging (or garments) and
exercise to encourage lymphatic functioning.4 CO can have a
severe impact on the daily lives of patients and their families,
affecting them physically, socially, and psychologically.2
CO and obesity
There is a growing recognition of CO occurring in the
obese population. Causes include: increased lymph produc-
tion rate as the capillaries overload the normal lymphatic
transport system, obesity causing raised venous pressure,
local venous insufficiency contributing to high lymphatic
flow, and lymphatic blockage (e.g., by surgery-associated
trauma).5 However, the true mechanisms which cause CO
have not been fully examined.
Obesity is a well-recognized international epidemic.6 In a
recent study assessing patients from specialist lymphedema
services in the United Kingdom, France, Italy, and Turkey,7
34.5% of patients were obese (body mass index [BMI]: 30–
39.9) and 18.4% were morbidly obese (BMI: >40).
This high prevalence in obesity causes an increase in the
prevalence of health-damaging comorbidities. As well as
edema, obese patients commonly have hypertension, type 2
diabetes, and cardiovascular disease.8,9 Obesity impairs qual-
ity of life (physically, mentally, and psychosocially): affecting
mobility, social interaction and self-esteem.10 Furthermore,
obese patients often find weight loss difficult to achieve or
maintain due to genetic and environmental influences (in-
cluding hormonal, metabolic, neural, and physical factors).11
It is a challenge for patients and clinicians to know how to
manage CO in obesity. Treating patients is often impractical
and inefficient through traditional methods, like DLT.12 Obese
patients often do not seem to have sustained improvement
following intensive compression bandaging. Although the
treatment is effective, the edema will recur if the issue of
obesity is not addressed.13 It is difficult for patients to manage
their own treatment, and for clinicians to modify compression
materials to exert the correct pressure on the limbs and to
achieve good outcomes with regard to quality of life.14
Bariatric surgery
As effective treatments are limited for this population, it
is more cost effective for patients to lose weight before
treatment plans are implemented.15 However, if they fail to
maintain weight loss through diet, exercise, or medication,
one option is to have bariatric (weight loss) surgery. The
aim of this surgery is to reduce food storage capacity by
reducing the size of the stomach, by performing a laparo-
scopic gastric bypass, gastric band insertion, or sleeve
gastrectomy.16
Bariatric surgery has a strong effect on metabolic and
hormonal systems, causing changes in: gastrointestinal hor-
mone secretion and metabolism of bile acid.17 It also affects
the hypothalamus-brain stem axis (which regulates energy
balance for food intake). This reduces energy intake and
improves glycemic control.18 Consequently, bariatric surgi-
cal procedures often result in patients losing and maintaining
weight loss, and achieving an improved quality of life and a
reduced range or severity of obesity-related comorbidities
(such as Type 2 diabetes and hypertension).10,19
Current prevalence literature
Although several studies have estimated the prevalence of
CO in an obese/bariatric population, and others have esti-
mated the prevalence of obesity in an edematous population,
most have methodological limitations.20–23 These limitations
include: a small sample size, unclear recruitment procedures,
or definitions of CO or lymphedema.
Inge et al.,24 O’Malley et al.,25 and Fife and Carter13
adopted and described clear methodologies, however the
prevalence estimates for CO in these groups of obese partici-
pants varied widely: 6.2% (93 of 1502), 33% (107 of 324), and
74% (11,100 of 15,000), respectively. These discrepancies
could be due to the researchers adopting different definitions of
CO or reliance on population medical records.
The authors of this article designed a prevalence study in a
bariatric population, with a clear CO definition and a defin-
itive recruitment method. The study was completed at the
East-Midlands Bariatric & Metabolic Institute (EMBMI) in
the Royal Derby Hospital (RDH), assessing patients new to
the bariatric service who received diet and psychological
advice in preparation for having bariatric surgery.
This study was part of LIMPRINT: Lymphedema IMpact
and PRevalence INTernational, a study under the Interna-
tional Lymphedema Framework. LIMPRINT has the aim of
identifying the prevalence and impact of CO within diverse
health services in different countries throughout the world.26
Objective
The study objective was to determine the prevalence and
impact of CO on the health-related quality of life (HQoL) of a
population of obese patients referred to a United Kingdom
bariatric service in RDH for consideration of surgery to re-
duce their morbid obesity.
Materials and Methods
Study population and recruitment
The study was approved by the Liverpool Central Research
Ethics Committee (Study IRAS ID: 198766) and took place at
the EMBMI (referred to hereafter as: the bariatric clinic) in
RDH. Patients were newly referred to the weight-management
clinical pathway. The clinic required patients: to have a BMI
of ‡40, or 35 kg/m2 with obesity-related comorbidities (e.g.,
diabetes and heart disease), and to have tried to lose weight
previously through diet, exercise, or medication. Clinic ap-
pointments consisted of consultations with a bariatric nurse,
physician, and dietician, who prepared them for having bariatric
surgery. Patients who scored highly on anxiety and depression
questionnaires, GAD-7 (Generalized Anxiety Disorder 7-Item
Scale) and PHQ-9 (Patient Health Questionnaire–9), were also
seen by a clinical psychologist.
The aim was to recruit 180 people, from new patients to the
service (normally 8 each week) over a 6-month period. To
reduce recruitment bias, the objective was to recruit a con-
secutive sample of patients. Recruitment took place during the
first clinic appointment of the weight management clinical
pathway, before bariatric surgery, while patients were waiting
to see one or more members of the bariatric team and/or at the
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end of their appointment. Recruitment commenced in August,
2016 and ended in March, 2017. The inclusion criteria con-
sisted of adult patients at their first clinic appointment, who
could give informed consent and who could understand En-
glish. The study was undertaken by one researcher trained in
lymphedema assessment methods (A.N.).
The study assessment methods consisted of a clinical as-
sessment, fluid measurements (through bioimpedance and
tissue dielectric constant techniques), and completion of
generic and edema-specific HQoL questionnaires. Each as-
sessment lasted 50–60 minutes.
Clinical assessment
To determine the presence and extent of CO, the researcher
assessed the presence of CO at the foot, ankle, lower limb
(below and above the knee), and abdomen. The pitting test
(primarily) and Stemmer’s sign techniques were used to as-
sess for the presence of CO. The pitting test was the gold
standard, used to define the cases of CO.
Medical and CO-related information were recorded to help
determine the cause(s) of and impact on the CO (if present):
blood test results, medical history, medication, and mobility;
and CO-related questions: history of cellulitis, duration of
CO, International Society of Lymphology (ISL) stage of CO,
skin conditions, and wounds. The ISL stages of CO27 are:
slight pitting edema that subsides with limb elevation (Stage I);
severe pitting edema, limb elevation alone rarely reducing
the edema (Stage II); and hard (fibrotic) tissue with skin
changes such as thickening and hyperpigmentation (Stage III).
Furthermore, the study team looked for conditions that may
cause CO, including: heart failure, history of cellulitis, and
obstructive sleep apnea; and medications that could exacerbate
CO, like calcium channel blockers.
Quality control checks were carried out by a clinical
lymphedema specialist (V.K.). All clinical data (including
foot/lower limb photographic records) were inspected by
V.K. to verify the presence/absence of CO and ISL staging.
Fluid measurements
Fluid measurements were taken to determine: which
technique was more effective at detecting the presence of CO
and whether they could be used to define chronic CO. These
results will be published separately.
Quality of life
Participants completed the following general and edema-
specific HQoL questionnaires: EQ-5D (EuroQOL-5 Dimen-
sions),28 LYMQOL (Lymphedema Quality of Life, if the
participants had CO),29 and SF-36 (RAND 36-Item Short
Form Health Survey, Version 1.0).30 Anxiety and depression
questionnaires, GAD-7,31 and PHQ-932 were completed as
part of their bariatric appointments.
As the study consisted of a heterogeneous population
sample, the SF-36 questionnaire scores were compared with a
normative dataset from the Health Survey for England (HSE)
1996,33 consisting of adults 16–74 years of age living in
private houses.
The EQ-5D, LYMQOL, and SF-36 questionnaires are used
extensively in lymphedema trials. They were completed to
enable comparisons to be made with other studies. EQ-5D is a
quality-of-life health index. LYMQOL is a lymphedema-
specific HQoL instrument, used for upper and lower limb CO
assessments, and to assess impact of CO on HQoL. The
questionnaire consists of: function, appearance, symptoms,
and mood (range: 1.0–4.0, no impact to maximum impact),
and HQoL (range: 1.0–10.0).
The SF-36 questionnaire measures physical health (range:
0–100.0, worst to best health scores). Although it is generic, it
is sensitive to change34 and covers many of the areas af-
fecting people with CO: physical functioning, role limitations
(RL) due to physical health, RL due to emotional problems,
energy/fatigue, emotional wellbeing, social functioning,
pain, and general health.
Using both edema-specific (LYMQOL) and generic (EQ-5D
and SF-36) questionnaires is valuable. Solely using generic
questionnaires may not prove sensitive enough to assess chan-
ges in a particular condition because they are designed to assess
HQoL across a variety of conditions. However, using condition-
specific questionnaires in combination with generic question-
naires should provide more sensitivity to change because they
have been designed with specific patient groups in mind.35
The GAD-7 and PHQ-9 questionnaires measured anxiety
and depression. The bariatric clinic patients completed them
as part of their appointment, therefore their data were ex-
tracted from the participants’ medical records.
Statistical analysis
The statistical programs, Stata and SPSS, were used. Data
from the pitting test (number of participants to have CO) were
analyzed to determine the proportion (with 95% confidence
intervals) of participants with CO. Student’s t and chi-squared
tests were applied to demographic characteristics and cellulitis
histories to compare participants with and without CO. T-tests
were calculated to compare the HQoL of participants with and
without CO to determine if the values differed significantly
(significance: £0.05). These t-tests analyzed the impact of CO
on HQoL, health utility, anxiety, and depression.
Chi-squared tests were applied to the data derived from
PHQ-9 Question 10: ‘‘If you checked off any problems, how
difficult have these problems made it for you to do your work,
take care of things at home, or get along with other people?’’
The tests were run to compare the HQoL of participants with
and without CO to determine the statistical significance.
Results
Prevalence of CO
Out of the 183 new patients attending the bariatric clinic
during the recruitment period, 48 met the inclusion criteria
and consented to take part, and 30 patients declined (Fig. 1).
The prevalence of CO in this bariatric population was 52.1%
(95% confidence intervals: 37.4%–66.7%) with 25 of the 48
participants having CO.
Demographic characteristics were recorded and statistical
tests run to compare participants with and without CO
(Table 1 and Supplementary Tables S1, S2). The comparison
demonstrated that those with CO had a higher age and weight
range, and a greater number of histories of cellulitis. Their
age range and cellulitis history were significantly different
than those without CO. The majority of participants with CO
were in the 50–60 kg/m2 BMI category (Table 2).
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Participants with CO had a greater number of positive
Stemmer’s signs (n = 6 compared with n = 1). They also had
severe skin conditions on their lower limbs, including chronic
lipodermatosclerosis (n = 6), lymphangiectasia (n = 2), and
hemosiderin staining (n = 1).
Severity of CO
Most of the 25 participants with CO had soft ISL Stage I
edema on their feet and shins (Fig. 1, n = 19). Other edema
locations included ankles and lower arms. Six participants
had ISL Stage II (n = 5) or ISL Stage III (n = 1) edema. Five
had chronic lipodermatosclerosis or lymphangiectasia,
however one participant with ISL Stage II edema only had
skin creases with severe pitting CO.
The duration of edema was recorded as ranging from less
than 6 months to greater than 10 years. One participant was
unaware of her edema. Only five participants had been told
the reason for their CO (including fluid retention, lymphe-
dema, and right knee surgery).
Potential contributors of CO
Blood test results, comorbidities, medications, and hor-
mone treatments were reviewed to highlight any that could
have contributed to the participants’ CO (Table 3). High brain
natriuretic peptide (BNP) levels in two participants with CO
were identified (671 and 862 ng/L), indicating that heart
failure may have contributed to their CO. Although a con-
siderable number of medications and hormone treatments had
FIG. 1. Screening log.
Table 1. Comparison of Characteristics Between Participants With and Without Chronic Edema






Gender 11 males: 14 females 6 males: 17 females p Value: 0.20










Histories of cellulitis 10 participants 1 participant p Value: 0.003
Bold: significant difference.
BMI, body mass index; CE, chronic edema; NCO, no chronic edema.
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a potential side effect of CO (Table 4), a comparison indi-
cated that these were commonly taken by participants with
and without CO. However, a higher percentage of partici-
pants with CO (24%) took calcium channel blockers com-
pared with participants without edema (10.9%). A higher
percentage of those with CO also took HMG-CoA reductase
inhibitors (statins) (24%, compared with 13%).
Impact of CO
A comparison between SF-36 study data and HSE nor-
mative data (Table 5) indicated that the study participants had
a much lower HQoL than others of the same age and gender
who were not morbidly obese.
EQ-5D data
There were no statistically significant differences in the
t-test values for EQ-5D Euroqol ( p = 0.91) and EQ-5D Health
State ( p = 0.91) between participants with and without CO
(Supplementary Table S3).
SF-36 data
There were no statistically significant differences in each
of the nine sections of the SF-36 data between participants
with and without CO: physical functioning ( p = 0.25), RL
due to physical health ( p = 0.99), RL due to emotional
problems ( p = 0.84), energy/fatigue ( p = 0.18), social func-
tioning ( p = 0.87), pain ( p = 0.90), general health ( p = 0.11),
and general health (compared with 1 year ago) ( p = 0.89)
(Supplementary Table S4). However, the t-test value for
emotional wellbeing ( p = 0.06) was approaching significance
and in a larger sample may be significant.
GAD-7 and PHQ-9 data
There were no statistically significant differences between
the participants with and without CO for the GAD-7 ( p = 0.22)
and PHQ-9 ( p = 0.61) t-test values, regarding anxiety and
depression (Supplementary Table S5). The chi-squared test for
PHQ-9 Question 10 ( p = 0.36) also indicated no statistically
significant difference (Supplementary Table S6).
LYMQOL data
T-tests could not be run on LYMQOL data as the question-
naire was designed to only be completed by participants with
CO. Instead, means of the lower limb LYMQOL data were
calculated to provide an evaluation of the impact of CO on the
participants’ function (2.1: medium impact), appearance (2.3:
medium), symptoms (1.9: low), mood (1.8: low), and HQoL
(5.9: medium) (Supplementary Table S7). The presence of CO
impacted the participants in varying levels, from not at all to a lot
(1.0–4.0), with the highest impact on function and appearance.
Upper limb data were not analyzed statistically due to low
sample size (n = 2). However, the highest impact on HQol for
the upper limb was on appearance and mood (means of 2.5
and 2.1 out of 4.0, respectively).






35–39.9 kg/m2 Class 2 obesity 1 0
40–50 kg/m2 Class 3 obesity
(severe)
23 10
50–60 kg/m2 Superobesity 20 13
>60 kg/m2 Superobesity 4 2
Total number of participants compared with those with CO are
identified next to their appropriate BMI class.
BMI classification reported by: World Health Organization.36
Table 3. Comparison of Potential Edema
Contributors Between Participants
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Beta blocker 4 13.0
Bisphosphonate 4.3
Calcium channel blockers 24 10.9






Nonsteroidal anti-inflammatories 6 10.9
Opiate (narcotic) analgesic 8.7
Opioid analgesic 4
Proton pump inhibitors 12 10.9
Xanthine oxidase inhibitor 4 4.3
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Discussion
Prevalence of CO
This study has confirmed that CO in a bariatric population is
common: 52.1% (n = 25 out of 183). However, the corre-
sponding confidence intervals gave a fairly wide 95% confi-
dence that the true prevalence was between 37.4% and 66.7%.
Previously, prevalence studies assessing the prevalence of
CO in obese populations included: Inge et al.,24 O’Malley
et al.,25 and Fife and Carter13 with prevalences of 6.2%, 33%,
and 74%, respectively. However, these studies have assess-
ment limitations. Inge et al.24 assessed undefined venous
edema, so it is unclear whether this was defined by a physical
assessment or participants’ symptoms or questionnaire
methods. O’Malley et al.25 relied on participants’ symptoms
(lower limb skin changes, feeling their lower limbs were
swollen, tight or heavy) (Tomás Ahern, personal communi-
cation). However, mild CO is not always apparent and cannot
be identified by participants consistently, therefore some CO
may have been missed. Fife and Carter13 based their preva-
lence data from medical records so consistent physical CO
assessment cannot be relied upon.
Table 5. Comparison of 36-Item Short Form Health Survey Scores and Health Survey
for England Normative Data

























Physical functioning 71.7 94 46.0 91 70.0 87 15.0 76
RL due to physical health 75.0 91 30.0 89 50.0 84 25.0 75
RL due to emotional problems 88.9 90 60.0 89 53.3 86 36.3 84




78.7 78 55.2 77 76.8 77 66.7 78
Social functioning 70.8 90 50.0 88 80.0 87 16.7 84
Pain 40.8 84 49.5 82 76.5 78 14.2 74
General health 36.7 74 36.0 73 50.0 69 40.0 64



















Physical functioning 61.3 90 53.0 90 47.0 87
RL due to physical health 62.5 90 30.0 88 50.0 84
RL due to emotional problems 58.3 84 46.7 85 26.7 85




57.0 73 72.0 73 53.6 73
Social functioning 56.3 85 72.5 86 50.0 86
Pain 73.1 80 33.5 80 40.5 78
General health 37.5 70 43.0 74 49.0 73



















Physical functioning 41.4 82 11.3 72 5.0 62
RL due to physical health 45.5 80 6.3 72 25.0 64
RL due to emotional problems 60.6 84 8.3 81 33.3 78




69.8 74 61.0 73 100.0 74
Social functioning 58.0 85 25.0 83 100.0 82
Pain 45.9 74 8.1 69 22.5 69
General health 39.1 70 35.0 65 45.0 64
The means of study SF-36 questionnaire scores were compared with normative data from HSE 1996 (HSE population norm).33
HSE, Health Survey for England; RL, role limitations; SF-36, 36-Item Short Form Health Survey.
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Although the prevalence figure obtained in this study dif-
fered from those outlined above, the study followed a clear
definition of CO and utilized robust physical assessment
methods with the gold standard pitting test and fluid mea-
surement techniques (bioimpedance and tissue dielectric
constant).
Severity and impact of CO
The high incidence of participants with CO having histo-
ries of cellulitis (n = 10 of 25, six with ISL Stage I edema, and
four with ISL Stage II edema) argues the importance of
managing CO with early intervention and treatment, to re-
duce the risk of further episodes of cellulitis. A study by
Burian et al.3 showed that severe stages of edema are asso-
ciated with cellulitis, but edema controlled by compression
reduces the risk of developing cellulitis, with the potential for
it not to occur at all.
Most of the 25 participants with CO were able to give a
rough estimate of the duration of their CO. However, one
participant was not aware of her CO (ISL Stage I, both feet)
and another knew about his ankle CO but had not noticed his
lower leg CO. This indicates that CO can begin and even
spread without people realizing, with the potential to cause
immobility and further comorbidities. Furthermore, both of
these participants produced low LYMQOL scores in the
impact (low, no impact) section, reflecting a good quality of
life as shown in the overall QoL (9, 10 out of 10) section. This
may imply that the participants who were not aware of their
CO, as well as those whose CO did not affect them, were
likely to have high QoL scores (as long as they did not as-
sociate any bodily pain with the CO).
It should be noted that nine participants with CO were
taking diuretics (Bumetanide, Furosemide, Indapamide,
and/or Spironolactone), medications sometimes used to
treat CO. For the eight participants that completed the
LYMQOL questionnaire (the ninth left before the study
assessment was completed), the scores indicate a high im-
pact of CO on their lives, demonstrated by each of the
sections (function, appearance, symptoms, mood, and
overall HQoL). Although commonly prescribed, diuretics
are not the best medication for treating CO (or improving
the HQoL of participants with CO), unless there are other
causes such as heart failure. DLT, including compression
bandaging, is the most effective treatment.4
Only five participants had been told the reason for their
CO. This implies that most of the participants (including four
out of the six participants with Stage II or III CO) had not
been referred to lymphedema clinics. Without proper help or
advice in improving their CO, it is likely to grow worse,
resulting in cellulitis, immobility, and skin conditions (like
chronic lipodermatosclerosis and lymphangiectasia).4
Lymphedema Quality of Life
This study confirms the high impact on HQoL on bariatric
patients, when assessed using the LYMQOL questionnaire,
which is sensitive to CO. The highest impact of CO on lower
limb HQoL was on function and appearance. This impact is
supported by Mercier et al.,37 whose study resulted in similar
LYMQOL data, which showed a high impact on the function
and appearance of participants who have lower limb edema.
Most participants (n = 19) had mild, pitting ISL Stage I
edema, with only six having moderate or severe ISL Stage II
or III edema. However, 10 participants with ISL Stage I
edema still produced high LYMQOL scores, indicating that
their CO had a severe impact on their HQoL. Even among the
six participants with ISL Stage II and III edema, the responses
were varied. One participant had medium HQoL (6.0) with
high function (3.0) and appearance (3.3) impact, medium
symptoms (2.4) impact, and low mood (1.8) impact. The sec-
ond participant left before completing the study assessment, but
the other four participants (including the participant with ISL
Stage III edema) scored low-impact (1.0–2.0) and high HQoL
(8.0–10.0) scores. Their awareness of their CO and their dif-
ferent comorbidities, mobility, and personalities should be ta-
ken into account, as multiple factors may contribute to the
development of CO and impact HQoL differently.37,38
Causal analysis
All study participants had obesity, which can have a dev-
astating impact on the lymphatic system, leaving the body
vulnerable to developing CO.39 However, heart failure (in-
dicated by high BNP blood test levels), comorbidities, hor-
mones, and medications may also have caused (or intensified)
the CO (Tables 3 and 4). Recent research has shown the
important relationship between cellulitis, the development of
CO and its relationship to a bariatric population.3
Two participants had high BNP levels (671 and 862 ng/L)
when their blood test levels were reviewed as part of their
study assessment. Both were still being treated for heart
failure, male and female participants, who had a heart attack
9 years before the study assessment and right heart failure 6
months before the study assessment, respectively. Their heart
failure would have contributed to their CO.40
As stated earlier, venous pressure, venous insufficiency,
and surgery are known causes for CO occurring in the obese
population.5 This matches the study results as six participants
suffered from venous disease: venous flow dysfunction ini-
tiating skin changes (like chronic lipodermatosclerosis and
hemosiderin staining) and, in severe cases, lymphatic dys-
function.4 Three participants had histories of having an ac-
cident or knee surgery, which can cause trauma and
dysfunction to the lymphatic system.5
Furthermore, obesity leads to less mobility, which leads to
less exercise of the calf muscles, causing poor venous cir-
culation, lymphatic return, and CO.41 Again, this links with
the study as 14 participants with CO suffered from upper and
lower body immobility.
Among the medications listed in Table 4, more participants
with CO took calcium channel blockers and HMG-CoA re-
ductase inhibitors (statins) (both 24%) than those without CO
(10.9% and 13%, respectively). Calcium channel blockers
are a major group of drugs, prescribed to lower blood pres-
sure. One of their major side effects is that they cause CO by
peripheral arteriolar vasodilation.42 Edema is also known to
be a side effect of the statins, Atorvastatin and Simvastatin
(0.1%–1% and 1%–10%, respectively).43
Five out of six participants with ISL Stage II and III edema
had mobility limitations, venous disease, and/or were taking
CO-contributing medications (calcium channel blockers and
HMG-CoA reductase inhibitors). However, one participant
with ISL Stage II edema did not appear to have any
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comorbidities or medications that would have caused/
affected the CO. Furthermore, a large number of participants
(n = 19) were taking CO-contributing medications but they
did not have CO. An article by Moffatt et al.38 states that
many complex factors can contribute to the development of
CO. A variety of causative factors can be involved, including
heart failure, hypertension, immobility, medications, and
even genetic and venous factors.
Lymphedema-associated BMI threshold
Greene et al.44 performed a study that demonstrated a
‘‘lymphedema-associated BMI threshold,’’ an association
between BMI and impaired lymphatic function (resulting in
CO). The results of this study are compared with the study
results for this article, to test the threshold alongside the study
paper BMIs.
Greene et al.44 assessed 33 obese patients, with a BMI
greater than 30 kg/m2, for the presence of lymphedema, using
lymphoscintigraphy scans. The group consisted of patients
who were at their maximum BMI (had not yet lost weight
through bariatric surgery or diet), which is similar to the study
article’s patients. Abnormal lymphatic function was defined
as: the radiolabeled colloid (used in the scan) taking longer
than 45 minutes to travel through the lymphatic channels,
dermal backflow, and/or the presence of tortuous lymphatic
channels with evidence of collateral flow through alternate
pathways.
Of the four patients with BMIs between 50 and 60 kg/m2,
two had normal and two had abnormal lymphatic function,
indicating a BMI threshold at which lymphatic dysfunction
begins (Table 6).
Investigating and comparing the results of both studies is
not straightforward. Although 23 participants in our study
had BMIs between 40 and 50 kg/m2 and therefore would have
had ‘‘normal’’ lymphoscintigrams according to the Greene
et al.44 study, 10 of the study participants had CO (Table 7).
Greene et al.44 used qualitative lymphoscintigraphy in
their study, which visualizes lymph nodes and vessels.45 The
authors seemed to suggest that having a normal lym-
phoscintigram result meant that the participants did not have
CO. However, patients can have CO with a normal lym-
phoscintigram.45 Venous hypertension leads to increased
lymph flow until the maximum capacity is reached. If cap-
illary filtration exceeds lymphatic drainage, CO develops
even if lymphatic drainage is increased above baseline levels
(high output failure of the lymphatic system). In fact, this is
theoretically the stage when the edema could be reversible. If
high output failure persists, the lymphatics become damaged
resulting in irreversible CO (lymphedema).38
Comparing the BMIs of Greene et al.44 and this study
article, both sets of participants were obese with high BMI
ranges (30–83.3 kg/m2 BMI and 37.2–66.9 kg/m2 BMI, re-
spectively). However, the study populations had different
thresholds for CO occurring. Not only did the study article
participants have CO in the ‘Normal’ BMI range (Table 7), but
half of the participants in the ‘Abnormal’ range did not have
CO. One explanation could be that other factors, such as co-
morbidities and medications, can contribute to the production
of edema and may alter the apparent BMI threshold.38
Impact on quality of life
As presented in Table 5, most of the study SF-36 ques-
tionnaire scores were lower than the HSE population nor-
mality scores, highlighting that the bariatric patients had a
poor HQoL compared with the normal population. Even
within the constraints of a small sample size, the participants’
HQoL was low, impacting each area of life (physical, energy,
and pain), including psychosocial health (emotional and so-
cial). This shows the big impact of morbid obesity on HQoL,
vastly different from the normative population.10
The HQoL of participants with CO was not significantly
different from participants without CO. One explanation is
the mild nature of the CO (n = 19 out of 25). The participants’
HQoL was already impacted by morbid obesity, immobility,
and comorbidities (like diabetes and heart disease), so their
CO did not greatly affect their HQoL. Although the impact of
CO could not be realized in this study, other studies have
demonstrated that those living with CO experience a poor
HQoL, especially regarding appearance and symptoms in the
upper limb CO, and function and appearance in the lower
limb CO. An increased level of CO leads to an increased
impact on HQoL.37,46
Managing the CO of bariatric patients is always complex
and challenging. Obesity impacts significantly on treatment,
as using traditional methods like DLT are not effective long
term.47,48 A study by Morgan et al.47 demonstrated that
professionals always struggle to know how to treat these
patients and have to adapt traditional treatments to battle with
limb distortion and complex comorbidities. The patients are
associated with complex presentations of CO, which result in
longer treatment episodes and poor outcomes. This impacts
on their quality of life, particularly their psychosocial health
and social life.
Comparison of populations
Keeley et al.7 performed a study that provided the profile of
patients from specialist lymphedema services in the United
Kingdom, France, Italy, and Turkey. Table 8 compares the
United Kingdom lymphedema service population from
Keeley et al.7 with the bariatric population recruited to this
study.
Table 6. Summary of Greene et al.44 Results
Greene et al. (2015)
lymphoscintigram result
BMI




Table 7. Comparison of Greene et al.44 and Study
Article with Lymphoscintigram Values
Greene et al. (2015) values Study participants
Normal (40–50 kg/m2) 43.5% (10/23)—Edema
Abnormal/normal (50–60 kg/m2) 65% (13/20) —Edema
Abnormal (>60 kg/m2) 50% (2/4) —Edema
The BMI values highlighted by Greene et al.44 lymphoscintigram
results and the results of the study presented in this article were
compared. (N = 47, as one participant had a BMI <40 kg/m2).
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Although both populations had a comparable level of
obesity (morbid obesity), the bariatric population were
younger ( p value: <0.001) and had significantly different ISL
stages ( p value: <0.001). The lymphedema service popula-
tion had greater ISL Stages II and III (n = 53 and 16), com-
pared to the bariatric population with greater ISL Stage I
(n = 19). Furthermore, the left Stemmers sign was signifi-
cantly different ( p value: <0.001) and the right Stemmers
sign almost significant ( p value: 0.069). For left and right
sides, the lymphedema service population had a greater
number of positive than negative Stemmers signs and the
bariatric population more negative than positive. This cor-
responds with the lymphedema service population consisting
of patients with more severe CO (ISL Stages II and III).
This comparison highlights the different levels of CO se-
verity in the lymphedema service and bariatric populations.
Although both were morbidly obese, the bariatric population
had a milder CO, indicating that having a high BMI does not
necessarily mean a greater severity of CO. It is unclear why
these populations were different. As they had similar BMIs,
the CO severity was expected to be similar. However, the
comparison has shown that the lymphedema services see
morbidly obese patients with severe CO and the bariatric
service sees morbidly obese patients with mild CO.
Identification of CO among morbidly obese patients
needs to be integrated into clinical assessments. Early rec-
ognition by weight management programs and management
by intervention (compression, DLT, self-care) may alleviate
the CO and prevent it from progressing to the more severe,
‘difficult-to-treat’ stages that lymphedema services often
see.4
Study limitations
Recruitment in this study was challenging due to the
following: assessment length, busy bariatric clinic schedule,
and clinic structure. Of the 183 patients, 30 patients de-
clined. Reasons included: patient was in pain and needed to









(n = 25 of 48)
Age
Number of participants 76 25
Mean (standard deviation) 64.1 (12.8) 51.1 (8.8)
Mean difference (95% CI) 13.0 (7.6, 18.5)
T-test score (degrees of freedom) 4.73 (99)
p Value <0.001
No. of participants (%)
Chi-squared
test score
(degrees of freedom) p Value
Gender
Female 53 (69.7) 14 (56.0)
Male 23 (30.3) 11 (44.0) 1.59 (1) 0.21
Mobility
Missing data 20
Requires aid 33 (58.9) 12 (48.0)
Walks freely 23 (41.1) 13 (52.0) 0.84 (1) 0.36
Arm mobility
Missing data 1
Full 49 (65.3) 17 (68.0)
Limited 26 (34.7) 8 (32.0) 0.06 (1) 0.81
ISL scale
I 7 (9.2) 19 (76.0)
II 53 (69.7) 5 (20.0)
III 16 (21.1) 1 (4.0) 44.0 (2) <0.001
Stemmers sign (R)
Missing data/equivocal 10 1
Negative 27 (40.9) 15 (62.5)
Positive 39 (59.1) 9 (37.5) 3.30 (1) 0.069
Stemmers sign (L)
Missing data/equivocal 10 1
Negative 24 (36.4) 19 (79.2)
Positive 42 (63.6) 5 (20.8) 12.9 (1) <0.001
Comparison between United Kingdom LIMPRINT patients (with completed ISL scale) and Study CO patients. All patients were
classified as having morbid obesity.
Bold: significant difference.
CI, confidence interval; ISL, International Society of Lymphology; LIMPRINT, Lymphedema IMpact and PRevalence INTernational.
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leave, and time issues. For seven other participants, the
researcher and bariatric team made management decisions
on the clinic day not to ask them to take part in the study.
Reasons included: the patients being in pain, stressed, or
immobile. A large number of patients (n = 68) were not re-
cruited due to the following reasons: they were not ap-
proached due to the busy clinic, the patients could not wait
for the length of the assessment, or the researcher was un-
available to assess them.
The small sample size (n = 48) means that caution should
be given when generalizing the results. Roughly eight new
patients attended the clinic each week, but only two to three
patients were recruited per week, depending on clinic
schedule organization and the number of new patients. Pa-
tients that were likely to consent to take part in the study were
those who did not need to leave quickly (no work that day, no
concern of car parking costs).
Conclusion
This study was established to determine the prevalence and
impact of CO on the HQoL of a population of bariatric pa-
tients. Although this complex population was challenging to
study, a high prevalence of CO was highlighted in the bar-
iatric service. The participants’ HQoL was impacted in
varying degrees by the CO, with most participants having
mild pitting CO. The major impact on CO was obesity, im-
mobility, and calcium channel blocker medications. The SF-
36 study data highlighted the low HQoL of the participants,
indicating the big impact of morbid obesity on HQoL.
Even though most CO was mild, over 50% of study par-
ticipants had CO. This points to an unrecognized problem in
the bariatric service. Identification needs to be integrated into
the bariatric assessment to prevent any CO from becoming
unnecessarily worse. Managing CO early also reduces the risk
of developing cellulitis. It is imperative that clinical staff are
trained in how common CO and associated skin conditions are
in obese patients and that they are treatable. They need to
recognize the preventable impact that immobility, medication,
and obesity can have on the lymphatic system. Furthermore, in
lymphedema services, patients with a high BMI end up having
severe CO. It is important to discover why lymphedema and
bariatric service populations have different CO severity, even
though they have common BMIs.
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